News

Eli Lilly Stock Offers Buying Opportunity For Goldman Sachs. Concerns Over CVS Setback Are Overblown, Analysts Say
Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...
BioSpace7h
WHO Leaning Toward Adding Obesity Drugs for Adults to Essential Medicines List: Reuters
In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...
What’s Happening With LLY Stock?
LLY has delivered impressive returns of 15% year-to-date, outperforming the S&P 500’s 5% decline during the same period. This ...
BioSpace1d
Lilly’s Revenue Leaps 45% Thanks to Zepbound, Mounjaro, Of Course
To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 ...
Zacks.com on MSN1d
LLY's Q1 Earnings Miss, Mounjaro & Zepbound Drive Sales, Stock Down
Eli Lilly misses first-quarter estimates for earnings but beats the same for sales. Mounjaro and Zepbound sales beat ...